Garden Convertible Bonds: Number of copies resold: 100
Zhejiang Huayuan Biomedical Co., Ltd. announced the resale results of “Huayuan Bonds”. The resale price is 100.103 yuan/sheet, the number of valid declarations is 100, and the resale amount is 10,010.30 yuan. The resale funds will arrive on May 29, 2024, and the resale funds will be credited to the investor's account on May 31. The resale will not have a significant impact on the company.
“Garden Convertible Bonds”: Stock conversion will resume on May 27, 2024
Zhejiang Garden Biopharmaceutical Co., Ltd. announced that “Huayuan Bonds” will resume share conversion on May 27, 2024. Previously, share conversion was suspended from May 20 to 24 due to the resale filing period. The company has granted the holder the right to resell once, and resumed the share conversion function on the next trading day after the end of the resale reporting period.
The China Securities Convertible Bonds Index opened up 0.01%, while Zhengdan Convertible Bonds and Investment Convertible Bonds rose more than 4%; Huayuan Convertible Bonds and Red Phase Convertible Bonds fell by more than 1%.
The China Securities Convertible Bonds Index opened up 0.01%, while Zhengdan Convertible Bonds and Investment Convertible Bonds rose more than 4%; Huayuan Convertible Bonds and Red Phase Convertible Bonds fell by more than 1%.
Garden Convertible Bonds: The conversion price was adjusted from 15.05 yuan/share to 13.56 yuan/share
Zhejiang Huayuan Biomedical Co., Ltd. announced that the conversion price of “Huayuan Bonds” was adjusted from 15.05 yuan/share to 13.56 yuan/share. The implementation date of this share transfer price adjustment is May 17, 2024.
Garden Convertible Bonds: The registration period for the resale is from May 20 to May 24
Zhejiang Huayuan Biomedical Co., Ltd. announced that the registration period for the resale of “Huayuan Bonds” is from May 20, 2024 to May 24, 2024, and the repurchase transfer date is May 30, 2024.
Garden Biology (300401.SZ): In the future, we will unswervingly promote the dual layout of “chemical synthesis and biosynthesis”
Gelonghui, May 9, 丨 Garden Biology (300401.SZ) said on the investor interactive platform that the company's existing products mainly use chemical synthesis. In the future, the company will unswervingly promote the dual layout of “chemical synthesis and biosynthesis”. Currently, it has invested abroad to establish a joint venture “Zhejiang Garden Biotechnology Co., Ltd.” to increase the company's market and technology development efforts in the field of amino acid and vitamin biosynthesis. At the same time, the company plans to invest in the construction of a “pilot base project with an annual output of 10,000 tons of L-alanine (fermentation method) and biological manufacturing”, which uses advanced biological manufacturing methods.
Garden Biotech (300401.SZ) 2023 equity distribution: $0.71 for every 10 shares, shares registered on May 14
According to the Zhitong Finance App, Huayuan Biotech (300401.SZ) announced that the company's 2023 equity distribution plan is to distribute a cash dividend of 0.71 yuan to all shareholders for every 10 shares based on the total share capital on the registration date of the company's equity distribution. The share registration date for this equity distribution is: May 14, 2024, and the excluding dividend date is: May 15, 2024.
Express News | Garden Biology: It has invested abroad to establish a joint venture to increase market and technology development in the field of amino acid and vitamin biosynthesis
Garden Convertible Bonds: The first bondholders' meeting in 2024 reviewed and passed the relevant bill
Zhejiang Huayuan Biomedical Co., Ltd. announced that the first “Huayuan Bonds” 2024 bondholders' meeting has been held. The meeting reviewed and passed the “Proposal on Adjusting the Use of Fund-raising Projects and Adding New Fund-raising Projects”.
Guolian Securities released a research report on April 17 stating that it gave Garden Biotech (300401.SZ) a holding rating. The main reasons for the rating include: 1) the sluggish economy and rising costs dragged down performance. The Q1 report in '24 ac
Guolian Securities released a research report on April 17 stating that it gave Garden Biotech (300401.SZ) a holding rating. The main reasons for the rating include: 1) the sluggish economy and rising costs dragged down performance. The Q1 report in '24 achieved remarkable results in reducing costs; 2) laying out synthetic biology projects, and continuing to advance convertible bond projects; 3) the VD3 main business still has high barriers and high growth logic. (Mainichi Keizai Shimbun)
Garden Biology (300401): Remarkable cost reduction results. The VD3 industry chain is sluggish, but high barriers still exist
Incident: The company released its 2023 annual report and 2024 quarterly report. In 23, the company achieved operating income of 1.09 billion yuan, a year-on-year decrease of 23%; realized net profit of 192 million yuan, a decrease of 50% over the previous year; withheld from the mother
Garden Convertible Bonds: A holders' meeting is scheduled to be held on May 6
Zhejiang Huayuan Biomedical Co., Ltd. announced that it has decided to hold the first “Huayuan Bonds” 2024 bondholders' meeting on May 6, 2024 to review the “Proposal on Adjusting the Use of Fund-raising Projects and Adding New Fund-raising Projects”.
Garden Biotech (300401.SZ): Net profit of 91.4831 million yuan in the first quarter increased 76.41% year-on-year
On April 15, Ge Longhui (300401.SZ) released its report for the first quarter of 2024. Operating revenue for the reporting period was 330 million yuan, up 4.15% year on year; net profit attributable to shareholders of listed companies was 91.4831 million yuan, up 76.41% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 610.303 million yuan, up 41.29% year on year; basic earnings per share were 0.17 yuan.
Garden Biology (300401.SZ): Net profit for 2023 fell 49.87% to 192 million yuan, and plans to distribute 10 to 0.71 yuan
On April 15, Ge Longhui (300401.SZ) announced its 2023 annual report. In 2023, the company achieved operating income of 1,095 million yuan, a year-on-year decrease of 22.78%; net profit attributable to shareholders of listed companies was 192 million yuan, a year-on-year decrease of 49.87%; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 148 million yuan, a year-on-year decrease of 57.65%; basic income per share was 0.35 yuan; it plans to distribute a cash dividend of 0.71 yuan (tax included) to all shareholders for every 10 shares.
Huayuan Biotech (300401.SZ) Performance Report: 2023 net profit of 192 million yuan decreased by 49.96% year-on-year
Gelonghui March 20 丨 Garden Biotech (300401.SZ) announced its 2023 annual results report. During the reporting period, the company achieved total operating revenue of 1,095 million yuan, a decrease of 22.78% over the same period of the previous year; achieved operating profit of 207 million yuan, a decrease of 52.61% over the same period of the previous year; realized total profit of 211 million yuan, a decrease of 52.39% over the same period of the previous year; and realized net profit attributable to shareholders of listed companies of 192 million yuan, a decrease of 49.96% over the same period last year. At the end of the reporting period, the company's total assets were 526,01864 million yuan, an increase of 27.31% over the beginning of the period; ownership
Express News | Garden Biotech: Net profit forecast to increase 67.76% - 96.69% in the first quarter of 2024
Garden Biology (300401.SZ): The total cost of the repurchase was about 100 million yuan to repurchase 1.69% of the shares
Gelonghui, March 7, 丨 Garden Biotech (300401.SZ) announced that as of March 6, 2024, the number of shares repurchased by the company through centralized bidding transactions was 9,307,200 shares, accounting for 1.69% of the company's current total share capital. The minimum transaction price was 10.09 yuan/share, the highest transaction price was 11.83 yuan/share, and the total transaction amount was about RMB 100 million (including transaction fees). The company has completed this repurchase. The actual repurchase period is from September 14, 2023 to March 6, 2024.
Garden Biology (300401.SZ): 1.69% of shares have been repurchased cumulatively
Gelonghui, March 4, 丨 Garden Biotech (300401.SZ) announced that as of February 29, 2024, the number of shares repurchased by the company through centralized bidding transactions was 9,307,200 shares, accounting for 1.69% of the company's current total share capital. The minimum transaction price was 10.09 yuan/share, the highest transaction price was 11.83 yuan/share, and the total transaction amount was RMB 100 million (including transaction fees).
Garden Biology (300401): Short-term VD3 and pharmaceutical sector performance is under pressure, and the long-term development path is clear
The short-term performance of the main business and Huayuan Pharmaceutical is under pressure. Recently, the company released a 2023 performance forecast. Net profit due to mother is expected to reach 180 million yuan to 220 million yuan, a year-on-year decrease of 53.09%-42.67%; after deducting non-net profit, it will be 1
Zhejiang Garden Biopharmaceutical's Unit Gets Nod for Eight New Products
Zhejiang Garden Biopharmaceutical's (SHE:300401) unit, Zhejiang Garden Nutrition Technology, obtained approval for eight of its new feed additive products. The products are feed additives with vitamin
No Data